Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Soft tissue sarcoma (STS) treatment remains challenging.
• Ifosfamide and mesna are established chemotherapeutic agents.
• Optimizing STS treatment regimens is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of ifosfamide plus mesna in soft tissue sarcoma.
• To assess the impact of adding doxorubicin to ifosfamide-based therapy.
• To report on the incidence and characteristics of adverse events, specifically encephalopathy.

Main Methods:

• Retrospective analysis of 67 patients treated with ifosfamide (5 or 8 g/m2) and mesna (400 or 600 mg/m2).
• Prospective evaluation of 60 patients receiving escalating doses of doxorubicin (20-60 mg/m2) combined with ifosfamide and mesna.
• Treatment involved 3-weekly cycles with continuous infusions and diuresis maintenance.

Main Results:

• Initial ifosfamide plus mesna regimen showed a 38% response rate (6 complete responses, 10 partial responses) in 42 patients.
• Adding doxorubicin to ifosfamide therapy was investigated in 60 patients.
• Encephalopathy was observed as an adverse event in patients treated with both regimens.

Conclusions:

• Ifosfamide and mesna demonstrate activity in soft tissue sarcoma.
• The addition of doxorubicin to ifosfamide-based regimens warrants further investigation.
• Careful monitoring for and management of potential neurotoxicity, such as encephalopathy, is essential during treatment.